http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11369629-B2
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e4589b30807b53be5b8d5c09bfad19dc |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12P19-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y208-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-727 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-13 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P19-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-727 |
filingDate | 2020-11-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate | 2022-06-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a30b584f0a9e376ad711984f77deefe1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b5df54f882a55d4609f98fd9405db614 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c973198d9d4b5c885ddb47375f981bbb http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4c71558ad1634ffeb1512c1a768cc4aa http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d833a551f6423da1aed6fd52a9f14f28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f65ff5cc0d94879416b9887ed9e8d2ea |
publicationDate | 2022-06-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | US-11369629-B2 |
titleOfInvention | Enzymatic preparation of increased anticoagulant bovine sourced heparin |
abstract | A heparin structure with increased anticoagulant activity and method of making the same are disclosed. A heparin sample is provided and treated with a heparan sulfate sulfotransferase in an enzymatic reaction to add sulfuryl groups from a sulfuryl group source to the heparin sample, resulting in a heparin structure having above about 8% more 3-O-sulfo groups relative to wild-type bovine intestinal heparin. The added sulfuryl groups modify the heparin structure and increase the sample's binding to antithrombin III and its anticoagulant activity to be more similar and a viable alternative to porcine intestinal heparin. The modified heparin exhibits an anti-FXa activity and an anti-FIIa activity greater than about 180 U/mg, and a ratio of the anti-FXa activity to the anti-FIIa activity of about 0.9 to about 1.1, consistent with U.S. Pharmacopeia (USP) heparin activity specifications. |
priorityDate | 2017-03-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 80.